Stx107 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 206 | 脆弱X症候群 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01325740 (ClinicalTrials.gov) | May 2011 | 28/3/2011 | A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome | A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of STX107 in Adults With Fragile X Syndrome | Fragile X Syndrome | Drug: STX107 | Seaside Therapeutics, Inc. | NULL | Suspended | 18 Years | 50 Years | Male | 16 | Phase 2 | United States |
| 2 | NCT00965432 (ClinicalTrials.gov) | September 2009 | 24/8/2009 | A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 | A Single-Dose, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study in Healthy, Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 | Fragile X Syndrome | Drug: STX107 | Seaside Therapeutics, Inc. | National Institutes of Health (NIH) | Completed | 18 Years | 50 Years | Male | 40 | Phase 1 | United States |